Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 18
2003 20
2004 20
2005 27
2006 24
2007 24
2008 26
2009 28
2010 28
2011 31
2012 24
2013 24
2014 21
2015 19
2016 17
2017 15
2018 7
2019 9
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

346 results
Results by year
Filters applied: . Clear all
Page 1
Immunological landscape and immunotherapy of hepatocellular carcinoma.
Prieto J, Melero I, Sangro B. Prieto J, et al. Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):681-700. doi: 10.1038/nrgastro.2015.173. Epub 2015 Oct 20. Nat Rev Gastroenterol Hepatol. 2015. PMID: 26484443 Review.
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J. Sangro B, et al. Among authors: prieto j. J Hepatol. 2013 Jul;59(1):81-8. doi: 10.1016/j.jhep.2013.02.022. Epub 2013 Mar 4. J Hepatol. 2013. PMID: 23466307 Clinical Trial.
Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J, Zhang N, Sun H, Su L, Zhang C, Xu H, Feng J, Wang M, Chen J, Liu L, Shan J, Shen J, Yang Z, Wang G, Zhou H, Prieto J, Ávila MA, Liu C, Qian C. Xiang J, et al. Among authors: prieto j. Gastroenterology. 2020 Feb;158(3):664-678.e24. doi: 10.1053/j.gastro.2019.10.025. Epub 2019 Oct 31. Gastroenterology. 2020. PMID: 31678303
Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.
Ballesteros-Briones MC, Martisova E, Casales E, Silva-Pilipich N, Buñuales M, Galindo J, Mancheño U, Gorraiz M, Lasarte JJ, Kochan G, Escors D, Sanchez-Paulete AR, Melero I, Prieto J, Hernandez-Alcoceba R, Hervas-Stubbs S, Smerdou C. Ballesteros-Briones MC, et al. Among authors: prieto j. Mol Ther. 2019 Nov 6;27(11):1892-1905. doi: 10.1016/j.ymthe.2019.09.016. Epub 2019 Sep 16. Mol Ther. 2019. PMID: 31563534
MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.
Erice O, Munoz-Garrido P, Vaquero J, Perugorria MJ, Fernandez-Barrena MG, Saez E, Santos-Laso A, Arbelaiz A, Jimenez-Agüero R, Fernandez-Irigoyen J, Santamaria E, Torrano V, Carracedo A, Ananthanarayanan M, Marzioni M, Prieto J, Beuers U, Oude Elferink RP, LaRusso NF, Bujanda L, Marin JJG, Banales JM. Erice O, et al. Among authors: prieto j. Hepatology. 2018 Apr;67(4):1420-1440. doi: 10.1002/hep.29533. Epub 2018 Feb 21. Hepatology. 2018. PMID: 28922472 Free PMC article.
Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications.
Alvarez-Sola G, Uriarte I, Latasa MU, Jimenez M, Barcena-Varela M, Santamaría E, Urtasun R, Rodriguez-Ortigosa C, Prieto J, Berraondo P, Fernandez-Barrena MG, Berasain C, Avila MA. Alvarez-Sola G, et al. Among authors: prieto j. Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1326-1334. doi: 10.1016/j.bbadis.2017.06.025. Epub 2017 Jul 12. Biochim Biophys Acta Mol Basis Dis. 2018. PMID: 28709961 Free article. Review.
Lysophosphatidic acid is a potential mediator of cholestatic pruritus.
Kremer AE, Martens JJ, Kulik W, Ruëff F, Kuiper EM, van Buuren HR, van Erpecum KJ, Kondrackiene J, Prieto J, Rust C, Geenes VL, Williamson C, Moolenaar WH, Beuers U, Oude Elferink RP. Kremer AE, et al. Among authors: prieto j. Gastroenterology. 2010 Sep;139(3):1008-18, 1018.e1. doi: 10.1053/j.gastro.2010.05.009. Epub 2010 Jun 19. Gastroenterology. 2010. PMID: 20546739
TMEM173 Alternative Spliced Isoforms Modulate Viral Replication through the STING Pathway.
Rodríguez-García E, Olagüe C, Ríus-Rocabert S, Ferrero R, Llorens C, Larrea E, Fortes P, Prieto J, González-Aseguinolaza G, Nistal-Villan E. Rodríguez-García E, et al. Among authors: prieto j. Immunohorizons. 2018 Dec 11;2(11):363-376. doi: 10.4049/immunohorizons.1800068. Immunohorizons. 2018. PMID: 31026807
Protein Abundance of Hepatic Drug Transporters in Patients With Different Forms of Liver Damage.
Drozdzik M, Szelag-Pieniek S, Post M, Zeair S, Wrzesinski M, Kurzawski M, Prieto J, Oswald S. Drozdzik M, et al. Among authors: prieto j. Clin Pharmacol Ther. 2020 May;107(5):1138-1148. doi: 10.1002/cpt.1717. Epub 2019 Dec 17. Clin Pharmacol Ther. 2020. PMID: 31697849
Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.
D'Avola D, López-Franco E, Sangro B, Pañeda A, Grossios N, Gil-Farina I, Benito A, Twisk J, Paz M, Ruiz J, Schmidt M, Petry H, Harper P, de Salamanca RE, Fontanellas A, Prieto J, González-Aseguinolaza G. D'Avola D, et al. Among authors: prieto j. J Hepatol. 2016 Oct;65(4):776-783. doi: 10.1016/j.jhep.2016.05.012. Epub 2016 May 17. J Hepatol. 2016. PMID: 27212246 Free article. Clinical Trial.
346 results
Jump to page
Feedback